Um Estudo para Investigar o Desfecho Clínico e a Qualidade de Vida em Doentes Chineses com CRSwNP Pós-operatório (PREDICT)

This is a prospective, multicenter real-world observational study .Patients will receive standard medical care as determined by the treating physician according to routine clinical practice at each site. No treatment assignment will be made as part of the study.

Patients will receive standard medical care as determined by the treating physician according to routine clinical practice at each site. No treatment assignment will be made as part of the study.

To describe the Sino-Nasal Outcome Test (SNOT)-22 total score at 52 weeks post- operatively.

[SNOT-22: score 0-5 each item, 5 means worse outcome, 22 items totally]

To describe the Modified Lund-Kennedy (MLK) score at 52 weeks post-operatively. [MLK score: score 0-24, 24 means worse outcome]

To describe the changes in post-operative symptom by Visual Analogue Scale(VAS) total sinus symptoms .

[VAS: score 0-10, 10 indicates worse outcome]

To describe the changes in post-operative by Nasal Polyp Score (NPS). [NPS: score 0-4, 4 indicates worse outcome]

To describe the changes in post-operative symptom by Visual Analogue Scale(VAS) Nasal blockage item .

[VAS: score 0-10, 10 indicates worse outcome]

To describe the changes in post-operative symptom by Sinonasal outcome test-22(SNOT-22) Smell/taste Item Score.

[SNOT-22: score 0-5 for each item, 5 means worse outcome]

To describe the changes in post-operative symptom by Sinonasal outcome test-22(SNOT-22) Nasal Congestion Item Score.

[SNOT-22: score 0-5 for each item, 5 means worse outcome]

To describe the changes in post-operative symptom by Nasal Congestion Score(NCS).

[NCS: score 0-3, 3 indicates worse outcome]

To describe the changes in post-operative symptom by Loss of Smell Item Score. [ Loss of Smell : score 0-3 for each item, 3 means worse outcome]

To describe the changes in post-operative symptom by Nasal Airway Resistance(NAR).

To describe the changes in post-operative CT Scores

To describe the changes in post-operative Quality of Life by SF-36((Short Form Health Survey), which is a widely used questionnaire to measure health-related quality of life.

To describe the changes in post-operative Quality of Life by Sinonasal outcome test-22(SNOT-22) top five items' frequency counts and average score.

[SNOT-22: score 0-5 for each item, 5 means worse outcome]

To describe the changes in post-operative Sleep Quality [SNOT-22: score 0-5 for each item, 5 means worse outcome]

To describe the post-operative medication use and need for surgery within one year post-operatively by the proportion of participants using Intranasal corticosteroids (INCS).

To describe the post-operative medication use and need for surgery within one year post-operatively by：

• The daily dosage (convert according to the equivalent dose of prednisone.) of participants used Systemic glucocorticoids (SCSs) for CRSwNP

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used Antibiotics for CRSwNP at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by

• Proportion of participants who used at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively.

To describe the post-operative medication use and need for surgery within one year post-operatively.

To describe the time to first recurrence and proportion of participants with recurrence

To describe the time to first recurrence and proportion of participants with recurrence

To describe the proportion of post-operative participants demonstrating clinically meaningful improvement at Week-52 and Week-4

To describe the proportion of post-operative participants demonstrating clinically meaningful improvement at Week-52 and Week-4 [SNOT-22: score 0-5 for each item, 5 means worse outcome]

To describe the proportion of post-operative participants demonstrating clinically meaningful improvement at Week-52 and Week-4 [VAS scale: 0-10,10 means worse outcome]

Post-operative complications by

•The proportion of participants with complications.

To describe asthma-related outcomes (for asthma participants only)

To describe asthma-related outcomes (for asthma participants only) [ACQ-5: score 0-6 for each item, 6 means worse outcome]

To describe the changes in post-operative ethmoid/maxillary sinuses (E/M) ratio.

To describe the changes in post-operative Olfactory Cleft Scores(NCS). [NCS: score 0-3, 3 means worse outcome]

To describe the post-operative medication use and need for surgery within one year post-operatively by the number of days of use intranasal corticosteroids (INCS).

To describe the post-operative medication use and need for surgery within one year post-operatively by：

• Proportion of participants who used Systemic glucocorticoids (SCSs) for CRSwNP at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by：

• The number of use days that participants used Systemic glucocorticoids (SCSs) for CRSwNP.

To describe the post-operative medication use and need for surgery within one year post-operatively by：

• Proportion of participants who used Systemic glucocorticoids (SCSs) for asthma at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by：

• The daily dosage (convert according to the equivalent dose of prednisone.) of participants used Systemic glucocorticoids (SCSs) for asthma

To describe the post-operative medication use and need for surgery within one year post-operatively by：

• The number of use days that participants used Systemic glucocorticoids (SCSs) for asthma.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The number of use days.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used Antibiotics for asthma at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The number of use days.

To describe the post-operative medication use and need for surgery within one year post-operatively by

• The number of use days.

To describe the post-operative medication use and need for surgery within one year post-operatively by

• Proportion of participants who used at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by

• The number of use days.

Post-operative complications by

•The types of post-operative complications.

Post-operative complications by

•The number of complication occurrences.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used at least once.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The frequency of use.

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The frequency of use.

Proportion of different inflammatory subtype at baseline.

Proportion of different inflammatory subtype at baseline.

Proportion of different inflammatory subtype at baseline.

Proportion of different inflammatory subtype at baseline.

Explore the characteristics/markers of recurrence within 1 year post-operate: such as gender, age, comorbidities (allergic rhinitis, asthma, NSAID-exacerbated respiratory disease, dermatitis/eczema, COPD, somnipathy etc.), phenotype, pre-operative scores, tissues (eosinophils (count: n/HPF; percentage: %), neutrophils (n/HPF; %) IL-4, IL-5, IL-13, IL-33, IL-17, TNF-α, IFN-γ,IL-25, TGF-β and TSLP ), serum (total IgE and specific IgE (IU/mL), ECP), blood (eosinophils (count: 10^9/L; percentage: %), basophils (10^9/L; %), neutrophils (10^9/L; %), monocytes (10^9/L; %), lymphocytes (10^9/L; %)) and S. aureus abundance

Explore the baseline characteristics and biomarkers related to surgical prognosis of patients:such as gender, age, comorbidities, phenotype, pre- operative scores, S. aureus abundance, different markers in nasal secretions, blood, and tissues

To summarize adverse events (AEs), adverse drug reactions (ADRs), and special situations associated with identified AstraZeneca products used for CRSwNP and/or asthma treatment, if any.

To summarize adverse events (AEs), adverse drug reactions (ADRs), and special situations associated with identified AstraZeneca products used for CRSwNP and/or asthma treatment, if any.

To describe direct Economic Burden.

To describe direct Economic Burden

To describe direct Economic Burden

To describe direct Economic Burden

To describe direct Economic Burden

To describe Healthcare Related Utilization

To describe Healthcare Related Utilization

To describe Healthcare Related Utilization

To describe Healthcare Related Utilization

To describe indirect burden